Adagio Medical Holdings Inc. has closed a $19 million private placement, led by existing and new healthcare-dedicated institutional investors. The company, a leader in catheter ablation technologies for cardiac arrhythmias, plans to use the proceeds to support submission activities for its FULCRUM-VT pivotal clinical study for premarket approval of the vCLAS™ ULTC System by the U.S. FDA. Additional funds will advance clinical experience and FDA submission for its next-generation ULTC catheter, build awareness of the technology, expand manufacturing, and strengthen corporate operations. The financing is expected to extend the company's cash runway and support key milestones.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020574694) on October 20, 2025, and is solely responsible for the information contained therein.
Comments